Combining a specific care management program with a commonly-prescribed drug for Alzheimer’s, memantine, multiplies the medication’s ability to improve daily function by about 7.5 times, stalling some of the disease’s most damaging effects, according to new research from NYU Langone Medical Center. With no significant new drug for Alzheimer’s having been approved since 2003, the study authors say the time has come for the field to pay more attention to methods that can improve the impact of existing drugs.

This post comes from the RSS feed of EurekaAlert, you can find more here!

Written by admin